Q/C Technologies, Inc., was legally incorporated in New Jersey as A.R.C Enterprises, Inc., on March 9, 1989. On July 22, 2024, the company changed to a Delaware corporation. The company is a clinical-stage pharmaceutical company dedicated to extending healthy lifespan. TNF focuses on the development and commercialization of two therapeutic platforms based on clearly defined therapeutic targets, isosinosine and Supera-CBD.
